Literature DB >> 16723586

Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.

Florence Doualla-Bell1, Ava Avalos, Tendani Gaolathe, Madisa Mine, Simani Gaseitsiwe, Ndwapi Ndwapi, Vladimir A Novitsky, Bluma Brenner, Maureen Oliveira, Daniella Moisi, Howard Moffat, Ibou Thior, Max Essex, Mark A Wainberg.   

Abstract

Among 16 human immunodeficiency virus-infected (subtype C) Batswana patients who failed nelfinavir (NFV)-containing regimens, the most prevalent mutation observed was D30N (54%), followed by L90M (31%). L89I, K20T/I, and E35D polymorphic changes were also identified. These findings suggest that subtype C viruses in Botswana may develop resistance to NFV via subtype-specific pathways.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16723586      PMCID： PMC1479146          DOI： 10.1128/AAC.01447-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.

Authors:  A Velazquez-Campoy; M J Todd; S Vega; E Freire
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 2.  Update of the Drug Resistance Mutations in HIV-1: 2005.

Authors:  Victoria A Johnson; Francoise Brun-Vezinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Deenan Pillay; Jonathan Schapiro; Amalio Telenti; Douglas Richman
Journal:  Top HIV Med       Date:  2005 Mar-Apr

3.  A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.

Authors:  Bluma Brenner; Dan Turner; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Mauricio Carobene; Richard G Marlink; Jonathan Schapiro; Michel Roger; Mark A Wainberg
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

4.  Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?

Authors:  V Novitsky; U R Smith; P Gilbert; M F McLane; P Chigwedere; C Williamson; T Ndung'u; I Klein; S Y Chang; T Peter; I Thior; B T Foley; S Gaolekwe; N Rybak; S Gaseitsiwe; F Vannberg; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000.

Authors:  Saladin Osmanov; Claire Pattou; Neff Walker; Bernhard Schwardländer; Jose Esparza
Journal:  J Acquir Immune Defic Syndr       Date:  2002-02-01       Impact factor: 3.731

6.  Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.

Authors:  Wolfgang Resch; Rainer Ziermann; Neil Parkin; Andrea Gamarnik; Ronald Swanstrom
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 7.  The impact of HIV-1 subtype on the clinical response on HAART.

Authors:  John Frater
Journal:  J HIV Ther       Date:  2002-11

8.  A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.

Authors:  Salman Muzammil; Patrick Ross; Ernesto Freire
Journal:  Biochemistry       Date:  2003-01-28       Impact factor: 3.162

9.  Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

Authors:  A K Patick; M Duran; Y Cao; D Shugarts; M R Keller; E Mazabel; M Knowles; S Chapman; D R Kuritzkes; M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.

Authors:  Hugues Loemba; Bluma Brenner; Michael A Parniak; Shlomo Ma'ayan; Bonnie Spira; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191
View more
  12 in total

1.  Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs.

Authors:  Nick C T Schopman; Anja Braun; Ben Berkhout
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease.

Authors:  Roxana M Coman; Arthur Robbins; Maureen M Goodenow; Robert McKenna; Ben M Dunn
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-03-30

3.  Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Peter K Quashie; Richard Bethell; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

4.  High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.

Authors:  Florence Doualla-Bell; Ava Avalos; Bluma Brenner; Tendani Gaolathe; Madisa Mine; Simani Gaseitsiwe; Maureen Oliveira; Daniella Moisi; Ndwapi Ndwapi; Howard Moffat; Max Essex; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

5.  HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.

Authors:  Irene Lisovsky; Susan M Schader; Jorge-Luis Martinez-Cajas; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

6.  Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).

Authors:  Jorge L Martinez-Cajas; Nitika P Pai; Marina B Klein; Mark A Wainberg
Journal:  J Int AIDS Soc       Date:  2009-06-30       Impact factor: 5.396

7.  HIV Genetic Diversity and Drug Resistance.

Authors:  André F Santos; Marcelo A Soares
Journal:  Viruses       Date:  2010-02-02       Impact factor: 5.818

8.  Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.

Authors:  Mark A Wainberg; Bluma G Brenner
Journal:  Viruses       Date:  2010-11-11       Impact factor: 5.048

9.  Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens.

Authors:  Florence Doualla-Bell; Tendani Gaolathe; Ava Avalos; Suzanne Cloutier; Ndwapi Ndwapi; Christina Holcroft; Howard Moffat; Diana Dickinson; Max Essex; Mark A Wainberg; Madisa Mine
Journal:  J Int AIDS Soc       Date:  2009-10-25       Impact factor: 5.396

10.  The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.

Authors:  Mark A Wainberg; Bluma G Brenner
Journal:  Mol Biol Int       Date:  2012-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.